Background: Spasticity following a stroke occurs in about 30% of patients. The mechanisms
underlying this disorder, however, are not well understood. Method: This review aims to …

Skeletal muscle relaxants are a heterogeneous group of medications used to treat two
different types of underlying conditions: spasticity from upper motor neuron syndromes and …

Myofascial pain syndrome (MPS) is characterized by myofascial trigger points and fascial
constrictions. At present, domestic and foreign scholars have not reached a consensus on …

Voluntary muscle is the largest human organ system. The musculotendinous contractual unit
sustains posture against gravity and actuates movement against inertia. Muscular injury can …

Baclofen is used for treatment of the spasticity of spinal origin that is a common sequela of
spinal cord injury and multiple sclerosis; spasticity occurs in about 50% of patients affected …

Background and objectives: Treatment of spasticity poses a major challenge given the
complex clinical presentation and variable efficacy and safety profiles of available drugs. We …

The present paper aims at providing an objective narrative review of the existing non-
pharmacological treatments for spasticity. Whereas pharmacologic and conventional …

Human cytochrome P450 1A2 (CYP1A2) is one of the major CYPs in the liver (&sim13%)
and metabolizes about 20% of clinically used drugs. CYP1A2 is a 515-residue protein with a …

Poststroke spasticity (PSS) is associated with significant consequences for a patient's
functional status and quality of life. Nonetheless, no uniform definition of spasticity exists that …

Background and objective Tizanidine, a centrally acting skeletal muscle relaxant, is
metabolized mainly by cytochrome P450 (CYP) 1A2 and has a low oral bioavailability. The …